CA2715203C - Antitumoral compounds - Google Patents

Antitumoral compounds Download PDF

Info

Publication number
CA2715203C
CA2715203C CA2715203A CA2715203A CA2715203C CA 2715203 C CA2715203 C CA 2715203C CA 2715203 A CA2715203 A CA 2715203A CA 2715203 A CA2715203 A CA 2715203A CA 2715203 C CA2715203 C CA 2715203C
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
hydrogen
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2715203A
Other languages
English (en)
French (fr)
Other versions
CA2715203A1 (en
Inventor
Alberto Rodriguez Vicente
Maria Garranzo Garcia-Ibarrola
Carmen Murcia Perez
Francisco Sanchez Sancho
Maria Del Carmen Cuevas Marchante
Cristina Mateo Urbano
Isabel Digon Juarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Publication of CA2715203A1 publication Critical patent/CA2715203A1/en
Application granted granted Critical
Publication of CA2715203C publication Critical patent/CA2715203C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
CA2715203A 2007-12-20 2008-12-19 Antitumoral compounds Active CA2715203C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07123882 2007-12-20
EP07123882.8 2007-12-20
PCT/EP2008/068065 WO2009080769A1 (en) 2007-12-20 2008-12-19 Antitumoral compounds

Publications (2)

Publication Number Publication Date
CA2715203A1 CA2715203A1 (en) 2009-07-02
CA2715203C true CA2715203C (en) 2015-09-08

Family

ID=40580474

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2715203A Active CA2715203C (en) 2007-12-20 2008-12-19 Antitumoral compounds
CA2710087A Active CA2710087C (en) 2007-12-20 2008-12-19 Antitumoral compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2710087A Active CA2710087C (en) 2007-12-20 2008-12-19 Antitumoral compounds

Country Status (26)

Country Link
US (4) US8710264B2 (enExample)
EP (3) EP2231633B1 (enExample)
JP (3) JP5529038B2 (enExample)
KR (3) KR101639772B1 (enExample)
CN (4) CN102190643B (enExample)
AT (1) ATE549313T1 (enExample)
AU (2) AU2008341671B2 (enExample)
BR (2) BRPI0821116B8 (enExample)
CA (2) CA2715203C (enExample)
CY (1) CY1117245T1 (enExample)
DK (2) DK2231590T3 (enExample)
ES (3) ES2384420T3 (enExample)
HR (2) HRP20140015T1 (enExample)
IL (3) IL206396A (enExample)
MX (2) MX2010006795A (enExample)
MY (3) MY148651A (enExample)
NZ (3) NZ597526A (enExample)
PL (2) PL2231590T3 (enExample)
PT (2) PT2231590E (enExample)
RS (2) RS53140B (enExample)
RU (3) RU2493147C2 (enExample)
SG (2) SG170778A1 (enExample)
SI (2) SI2231590T1 (enExample)
UA (3) UA106967C2 (enExample)
WO (2) WO2009080769A1 (enExample)
ZA (3) ZA201004017B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140015T1 (hr) 2007-12-20 2014-02-14 Pharma Mar, S.A. Antitumorski spojevi
WO2013103155A1 (en) * 2012-01-05 2013-07-11 Kao Corporation Agent for reduction of sensory irritation
MA38588B1 (fr) 2013-04-16 2018-04-30 Idorsia Pharmaceuticals Ltd Dérivés bi-aromatiques antibactériens
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
ZA938019B (en) 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5681847A (en) * 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US6380400B1 (en) 1998-09-11 2002-04-30 Victor Fedij Methods of making dihydropyrone HIV protease inhibitors
US6528510B1 (en) 1998-09-11 2003-03-04 Warner-Lambert Company HIV protease inhibitors
AU2000241948A1 (en) * 2000-04-04 2001-10-15 Novartis Ag Method for treating cells resistant to antineoplastic agents
MXPA04008577A (es) * 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
AU2004263287B2 (en) * 2003-07-25 2009-02-12 Novartis Ag Substituted lactams and their use as anti-cancer agents
RU2006142690A (ru) * 2004-06-03 2008-06-10 Козан Байосайенсиз Инкорпорейтед (Us) Соединения лептомицина
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
WO2007014423A1 (en) * 2005-08-02 2007-02-08 Medvet Science Pty, Ltd. Exercise apparatus
EP2404912A3 (en) 2006-06-16 2012-07-25 Pharma Mar S.A. Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds
HRP20140015T1 (hr) 2007-12-20 2014-02-14 Pharma Mar, S.A. Antitumorski spojevi

Also Published As

Publication number Publication date
NZ586012A (en) 2011-11-25
US20100280108A1 (en) 2010-11-04
BRPI0821114B1 (pt) 2021-09-08
JP2014133752A (ja) 2014-07-24
EP2231590B1 (en) 2012-03-14
HK1147990A1 (en) 2011-08-26
MY155342A (en) 2015-10-15
BRPI0821114B8 (pt) 2021-11-09
RU2493147C2 (ru) 2013-09-20
IL206397A (en) 2014-01-30
JP5529038B2 (ja) 2014-06-25
JP5860088B2 (ja) 2016-02-16
CN101903367A (zh) 2010-12-01
IL206396A (en) 2014-05-28
CN102174058A (zh) 2011-09-07
US9187445B2 (en) 2015-11-17
HK1180678A1 (en) 2013-10-25
IL206396A0 (en) 2010-12-30
US20120041063A2 (en) 2012-02-16
EP2231633B1 (en) 2013-10-30
JP5727228B2 (ja) 2015-06-03
IL206397A0 (en) 2010-12-30
MX2010006796A (es) 2010-10-26
UA106967C2 (uk) 2014-11-10
MY164533A (en) 2017-12-29
RU2013112003A (ru) 2014-08-20
DK2231590T3 (da) 2012-07-09
US20150344454A1 (en) 2015-12-03
ES2442140T3 (es) 2014-02-25
JP2011506575A (ja) 2011-03-03
CN102190643A (zh) 2011-09-21
PL2231633T3 (pl) 2014-03-31
SI2231590T1 (sl) 2012-10-30
RU2528393C9 (ru) 2015-01-10
EP2231633A1 (en) 2010-09-29
EP2597091A1 (en) 2013-05-29
IL229594A (en) 2016-02-29
AU2008341670B2 (en) 2012-04-19
PT2231590E (pt) 2012-06-25
UA104281C2 (ru) 2014-01-27
RU2528393C1 (ru) 2014-09-20
ZA201106371B (en) 2013-05-29
CN101903367B (zh) 2015-08-05
BRPI0821116B1 (pt) 2020-02-18
JP2011506578A (ja) 2011-03-03
CN101903337A (zh) 2010-12-01
HK1147998A1 (en) 2011-08-26
RS52343B (sr) 2012-12-31
SI2231633T1 (sl) 2014-02-28
ES2384420T3 (es) 2012-07-04
AU2008341671B2 (en) 2012-07-26
KR20150076265A (ko) 2015-07-06
SG170779A1 (en) 2011-05-30
HRP20120464T1 (hr) 2012-07-31
ZA201004018B (en) 2011-12-28
US9827257B2 (en) 2017-11-28
CA2710087A1 (en) 2009-07-02
BRPI0821116A2 (pt) 2015-08-11
MX2010006795A (es) 2010-10-26
AU2008341670A1 (en) 2009-07-02
CN101903337B (zh) 2013-12-18
KR101541436B1 (ko) 2015-08-03
IL229594A0 (en) 2014-01-30
US8710264B2 (en) 2014-04-29
RS53140B (sr) 2014-06-30
CN102190643B (zh) 2015-02-25
RU2010130180A (ru) 2012-01-27
KR101579553B1 (ko) 2015-12-22
RU2489429C2 (ru) 2013-08-10
WO2009080761A1 (en) 2009-07-02
BRPI0821116B8 (pt) 2021-05-25
SG170778A1 (en) 2011-05-30
CA2710087C (en) 2015-06-02
US20150342972A1 (en) 2015-12-03
KR101639772B1 (ko) 2016-07-15
MY148651A (en) 2013-05-15
UA119963C2 (uk) 2019-09-10
US9750759B2 (en) 2017-09-05
PT2231633E (pt) 2014-01-20
WO2009080769A1 (en) 2009-07-02
EP2231590B9 (en) 2012-08-15
DK2231633T3 (da) 2014-01-20
HRP20140015T1 (hr) 2014-02-14
BRPI0821114A2 (pt) 2015-06-16
EP2597091B1 (en) 2016-04-20
AU2008341671A1 (en) 2009-07-02
ATE549313T1 (de) 2012-03-15
KR20100125226A (ko) 2010-11-30
ES2578606T3 (es) 2016-07-28
EP2231590A1 (en) 2010-09-29
PL2231590T3 (pl) 2012-09-28
US20110034549A1 (en) 2011-02-10
ZA201004017B (en) 2011-12-28
RU2010130253A (ru) 2012-01-27
NZ586013A (en) 2012-02-24
KR20100100979A (ko) 2010-09-15
NZ597526A (en) 2012-06-29
CY1117245T1 (el) 2017-04-05
CA2715203A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
AU2008341670B2 (en) Antitumoral compounds
AU2012216670B2 (en) Antitumoral compounds
HK1147990B (en) Antitumoral compounds
ANTITUIMIORAL The present invention relates to new antitumoral compounds, pharmaceutical compositions containing them and their use as antitumoral agents.
HK1180678B (en) Antitumoral compounds
HK1147998B (en) Antitumoral compounds

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131001

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250619

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251105